OP0129 A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF RUZINURAD (SHR4640) IN COMBINATION WITH FEBUXOSTAT FOR PRIMARY GOUT AND HYPERURICEMIA WITH AN INADEQUATE RESPONSE TO FEBUXOSTAT ALONE

非布索坦 高尿酸血症 痛风 医学 安慰剂 双盲 内科学 尿酸 替代医学 病理
作者
Chunde Bao,Huihua Ding,Qingqing Dai,Jinling Hu,L. Yang,Z. Jiang,Xin Xu,Chuangxing Lin,Wei He,Qian Xie,Yan Zhuang,Xiaodong Shi,J. Wen,Li Yoong Tang,Guiyang Shi,Xinglishang He,Long Qian,Weixin Hu,Yan Ma,Guangbin Dong
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:83: 86-87 被引量:3
标识
DOI:10.1136/annrheumdis-2024-eular.4573
摘要

Background:

Despite the use of xanthine oxidase inhibitors (XOIs), a large proportion of gout patients fail to achieve or maintain the target serum uric acid (sUA) level. Adding a uricosuric agent to a XOI represents an attractive therapeutic strategy for XOI inadequate responders. Ruzinurad (SHR4640) is a highly selective and potent inhibitor against uric acid transporter 1 (URAT1, a major urate reabsorption transporter in kidney). In previous clinical studies, ruzinurad was well-tolerated and showed robust sUA lowering effect in patients with hyperuricemia [1, 2]. Moreover, the combination of ruzinurad and the XOI febuxostat exhibited a synergistic effect in reducing sUA [3].

Objectives:

This 12-week, multicenter, randomized, double-blind, placebo-controlled, phase 2 study aimed to assess the efficacy and safety of ruzinurad plus febuxostat in patients with primary gout and hyperuricemia with an inadequate response to febuxostat alone (NCT05513976).

Methods:

Gout adults with fasting sUA ≥390 µmol/L despite on stable dose of febuxostat (40, 60, or 80 mg/day) for ≥6 weeks were randomly assigned (1:1:1) to ruzinurad 10 mg, ruzinurad 5 mg, or placebo groups, stratified by the febuxostat dose at screening (40 vs. 60 vs. 80 mg). Administration of ruzinurad started with a low dose of 1 mg/day and was gradually up-titrated to the tested dose, whereas febuxostat was continued at the same dose at screening (Figure 1). All study medications were taken orally once daily for 12 weeks. The primary endpoint was proportion of patients achieving sUA level of ≤360 μmol/L at Week 12.

Results:

A total of 151 patients were randomized, and all received study treatment. Baseline characteristics were generally balanced among ruzinurad 10 mg, ruzinurad 5 mg, and placebo groups (male, 96.1%/95.9%/98.0%; mean age, 34.6/37.5/38.5 years; mean sUA, 514.1/514.0/504.8 μmol/L; eGFR <90 mL/min, 37.3%/36.7%/35.3%; tophi, 74.5%/67.3%/72.5%). At Week 12, significantly greater proportions of patients in the ruzinurad groups achieved the target sUA level of ≤360 μmol/L (56.9% in the 10 mg group and 53.1% in the 5 mg group) compared to the placebo group (13.7%; OR, 8.7 [95% CI, 3.3–23.2] and 7.1 [95% CI, 2.7–18.9], respectively; P < 0.0001 for both comparisons; Figure 2). Consistently, subgroup analyses based on baseline eGFR, sUA, and tophus demonstrated superior effects of ruzinurad over placebo. Proportions of patients achieving sUA level of ≤300 μmol/L at Week 12 were also greater in the ruzinurad groups (43.1% in the 10 mg group and 38.8% in the 5 mg group) versus placebo group (9.8%; OR, 7.2 [95% CI, 2.4–21.2] and 5.8 [95% CI, 1.9–17.2], respectively; nominal P=0.0001 and 0.0009, respectively; Figure 2). Treatment-emergent adverse events (TEAEs) occurred in 74.5%, 87.8%, and 80.4% of the patients in the ruzinurad 10 mg, ruzinurad 5 mg, and placebo group, respectively, with the most common being gout flares (39.2%, 49.0%, and 45.1%). The majority of TEAEs were mild or moderate. No TEAEs led to treatment discontinuation or death.

Conclusion:

Addition of the URAT1 inhibitor ruzinurad (both 10 and 5 mg) to febuxostat demonstrated superior sUA lowering effect versus placebo plus febuxostat and was generally well-tolerated in patients with primary gout and hyperuricemia uncontrolled on febuxostat alone.

REFERENCES:

[1] Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology. 2021; 60:5089-5097. [2] Tang H, Cui B, Chen Y, Chen L, Wang Z, Zhang N et al. Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study. Therapeutic Advances in Musculoskeletal Disease. 2022; 14:1759720X211067304. [3] Wang C, Yu Q, Jiang X, Deng Y, Sun F, Li X et al. A Drug–Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia. The Journal of Clinical Pharmacology. 2023; 63:239-249.

Acknowledgements:

NIL.

Disclosure of Interests:

Chunde Bao: None declared, Huihua Ding: None declared, Qing Dai: None declared, Jiankang Hu: None declared, Lei Yang: None declared, Zhenyu Jiang: None declared, Xiaoyan Xu: None declared, Changsong Lin: None declared, Hua Wei: None declared, Qibing Xie: None declared, Yu Zhuang: None declared, Xiaofei Shi: None declared, Jing Wen: None declared, Lin Tang: None declared, Guixiu Shi: None declared, Xiaohong He: None declared, Long Qian: None declared, Wen Hu: None declared, Yanlin Ma Jiangsu Hengrui Pharmaceuticals Co., Ltd., Guangchao Dong Jiangsu Hengrui Pharmaceuticals Co., Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lazyp完成签到 ,获得积分10
1秒前
1秒前
赘婿的应助被李一凡采纳,获得10
1秒前
jhlllllll发布了新的文献求助10
1秒前
kings发布了新的文献求助10
1秒前
虚幻慕凝发布了新的文献求助10
2秒前
molihuakai的应助被freak采纳,获得10
2秒前
大个的应助被翁雁丝采纳,获得10
3秒前
3秒前
OPO发布了新的文献求助10
4秒前
Maestro_S的应助被绒绒采纳,获得10
4秒前
4秒前
22222发布了新的文献求助10
4秒前
简单春天发布了新的文献求助10
5秒前
5秒前
LFG完成签到,获得积分10
5秒前
6秒前
7秒前
筑天完成签到,获得积分10
7秒前
7秒前
华仔的应助被MYY采纳,获得10
7秒前
闪闪的灵发布了新的文献求助10
7秒前
Tomi完成签到,获得积分10
8秒前
共享精神的应助被Yxblin采纳,获得10
8秒前
8秒前
Orange的应助被法就采纳,获得15
8秒前
8秒前
9秒前
9秒前
虚幻慕凝完成签到,获得积分20
9秒前
9秒前
lsq完成签到,获得积分10
10秒前
天天快乐的应助被公主抡大锤采纳,获得10
10秒前
木仓发布了新的文献求助10
10秒前
思源的应助被hamster666采纳,获得10
11秒前
贤君发布了新的文献求助10
11秒前
maT发布了新的文献求助10
11秒前
11秒前
Owen的应助被简单春天采纳,获得10
11秒前
张煜禾发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164445
求助须知:如何正确求助?哪些是违规求助? 9558283
关于积分的说明 21744871
捐赠科研通 7754979
什么是DOI,文献DOI怎么找? 3428582
关于科研通互助平台的介绍 2553119
邀请新用户注册赠送积分活动 2473142